多瑞醫藥(301075.SZ):擬出資560萬元成立控股子公司海瑞迪醫藥
格隆匯4月22日丨多瑞醫藥(301075.SZ)公佈,根據公司經營及戰略發展的需要,為充分利用、整合各方資源優勢,公司與湖北南藥新達藥業有限公司(簡稱“南藥新達”)共同出資設立成立湖北海瑞迪醫藥有限公司(簡稱“海瑞迪醫藥”)。
海瑞迪醫藥註冊資本800萬元。其中,多瑞醫藥認繳出資額560萬元,認繳比例70.00%,南藥新達240萬元,認繳比例30.00%。公司投資海瑞迪醫藥的資金來源於自有資金,海瑞迪醫藥成立後,其將成為公司的控股子公司。
海瑞迪醫藥經營範圍包括中藥飲片、中成藥、化學原料藥、化學藥製劑、抗生素原料藥、抗生素製劑、生化藥品批發(不含冷藏冷凍藥品)等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.